Safety considerations when treating myelofibrosis

Expert Opinion on Drug Safety

Volumn 15, Issue 9, 2016, Pages 1185-1192

  O'Sullivan J M ^a   McLornan, D P ^b   Harrison, C N ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

JAK inhibitors; myelofibrosis; ruxolitinib; safety

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANDROGEN; BUSULFAN; DANAZOL; FEDRATINIB; HYDROXYUREA; IMMUNOMODULATING AGENT; INTERFERON; IRON CHELATING AGENT; JANUS KINASE INHIBITOR; LENALIDOMIDE; MELPHALAN; MOMELOTINIB; PACRITINIB; PEGINTERFERON; POMALIDOMIDE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ERYTHROPOIETIN; RUXOLITINIB; THALIDOMIDE; 11-(2-PYRROLIDIN-1-YLETHOXY)-14,19-DIOXA-5,7,26-TRIAZATETRACYCLO(19.3.1.1(2,6).1(8,12))HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE; BENZAMIDE DERIVATIVE; BRIDGED COMPOUND; JANUS KINASE; N-(CYANOMETHYL)-4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZAMIDE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ANEMIA; BLEEDING; BRAIN HEMORRHAGE; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEART ARREST; HEART DISEASE; HEART FAILURE; HEMATOLOGIC DISEASE; HEPATITIS B; HERPES ZOSTER; HUMAN; IRON CHELATION; MYELOFIBROSIS; NEUTROPENIA; NON MELANOMA SKIN CANCER; OPPORTUNISTIC INFECTION; PERIPHERAL NEUROPATHY; PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETINITIS; REVIEW; SPLENOMEGALY; THROMBOCYTOPENIA; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; WERNICKE ENCEPHALOPATHY; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; PATHOPHYSIOLOGY; PRIMARY MYELOFIBROSIS;

BENZAMIDES; BRIDGED-RING COMPOUNDS; DRUG DESIGN; HUMANS; JANUS KINASES; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES;

EID: 84984638433     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2016.1185414     Document Type: Review

References (83)

1. J.Thiele, H.M.Kvasnicka, A.Tefferi, et al. Primary myelofibrosis. In:S.H.Swerdlow, E.Campo, N.L.Harris, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon:IARC; 2008. p. 44–47.
2. F.Cervantes How I treat myelofibrosis. Blood. 2014;124:2635–2642.
3. J.T.Reilly, M.F.McMullin, P.A.Beer, et al. British committee for standards in haematology, guideline for the diagnosis and management of myelofibrosis. Br J Haematol. 2012;158:453–471.
4. R.A.Mesa, M.N.Silverstein, S.J.Jacobsen, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia:an Olmsted County study, 1976–1995. Am J Hematol. 1999;61:10–15.
5. C.James, V.Ugo, J.P.Le Couedic, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–1148.
6. A.Tefferi, T.L.Lasho, C.M.Finke, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis:clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28:1472–1477.
7. J.Nangalia, C.E.Massie, E.J.Baxter, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–2405.
8. T.Klampfl, H.Gisslinger, A.S.Harutyunyan, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–2390.
9. A.Tefferi, T.L.Lasho, A.Tischer, et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood. 2014;124:2465–2466.
10. R.Rampal, F.Al-Shahrour, O.Abdel-Wahab, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123:123–133.
11. I.Chachoua, C.Pecquet, M.El-Khoury, et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood. 2016;127:1325–1335.
12. F.Cervantes, B.Dupriez, A.Pereira, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895–2901.
13. F.Passamonti, F.Cervantes, A.M.Vannucchi, et al. A dynamic prognostic model to predict survival in primary myelofibrosis:a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703–1708.
14. N.Gangat, D.Caramazza, R.Vaidya, et al. DIPSS plus:a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392–397.
15. A.Tefferi, T.Jimma, N.Gangat, et al. Predictors of greater than 80% 2-year mortality in primary myelofibrosis:a Mayo Clinic study of 884 karyotypically annotated patients. Blood. 2011;118:4595–459.
16. A.Tefferi, P.Guglielmelli, T.L.Lasho, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis:an international study of 570 patients. Leukemia. 2014;28:1494–1500.
17. N.Kröger, T.Giorgino, B.L.Scott, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood. 2015;125:3347–3350.
18. N.Kröger, J.H.Deeg, E.Olavarria, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis:a consensus process by an EBMT/ELN international working group. Leukaemia. 2015;29:2126–2133.
19. J.T.Reilly, M.F.McMullin, P.A.Beer, et al. Use of JAK inhibitors in the management of myelofibrosis:a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. Br J Haematol. 2014;167:418–420.•• Updated guideline recommending ruxolitinib as first-line treatment for myelofibrosis.
20. A.M.Vannucchi, J.J.Kiladjian, M.Griesshammer, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426–435.
21. S.Verstovsek, R.A.Mesa, J.Gotlib, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.•• COMFORT-I Trial.
22. European Medicines Agency Summary of Product Characteristics on ruxolotinib. Jakavi [Internet]. Novartis Pharmaceuticals UK Ltd. [cited 2012 Aug]. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002464/WC500133223.pdf
23. C.Harrison, J.J.Kiladjian, H.K.Al-Ali, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–798.•• COMFORT-II Trial.
24. S.Verstovsek, R.A.Mesa, J.Gotlib, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis:results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100:479–488.
25. F.Cervantes, A.M.Vannucchi, J.J.Kiladjian, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122:4047–4053.
26. S.Verstovsek, H.Kantarjian, R.A.Mesa, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117–1127.
27. A.M.Vannucchi, H.M.Kantarjian, J.J.Kiladjian, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100:1139–1145.• Pooled analysis of COMFORT Trials.
28. P.Guglielmelli, F.Biamonte, G.Rotunno, et al.; COMFORT-II Investigators. Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood. 2014;123:2157–2160.
29. M.F.McMullin, C.N.Harrison, D.Niederwieser, et al. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II:an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Exp Hematol Oncol. 2015;4:26.
30. A.Heine, P.Brossart, D.Wolf. Ruxolinitinib is a potent immunosuppressive compound:is it time for anti-infective prophylaxis? Blood. 2013;122:3843–3844.•• Immunosuppressive effects of ruxolitinib.
31. G.Caocci, F.Murgia, L.Podda, et al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia. 2014;28:225–227.
32. R.Wathes, S.Moule, D.Milojkovic. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med. 2013;369:197–198.
33. C.Keohane, S.Kordasti, T.Seidl, et al. JAK inhibition induces silencing of T helper cytokine secretion and a profound reduction in T regulatory cells. Br J Haematol. 2015;171:60–73.
34. K.Schonberg, J.Rudolph, I.Cornez, et al. The JAK1/JAK2 inhibitor ruxolitinib substantially affects NK cell biology. Blood. 2013;122:16.
35. A.Heine, S.A.Held, S.N.Daecke, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122:1192–1202.
36. A.Tefferi, A.Pardanani. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011;86:1188–1191.
37. S.Verstovsek, H.M.Kantarjian, Z.Estrov, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib:survival advantage in comparison to matched historical controls. Blood. 2012;120:1202–1209.
38. M.Kremyanskaya, J.Mascarenhas, R.Rampal, et al. Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis. Br J Haematol. 2014;167:144–146.
39. A.Mead, R.Clark, J.Chacko, et al. Response to ruxolitinib in patients with intermediate-1, intermediate-2 and high-risk myelofibrosis:results of the UK Robust trial. Br J Haematol. 2015;170:29–39.
40. V.Gupta, R.S.Tavares, M.Griesshammer, et al. Safety and efficacy of ruxolitinib retreatment after treatment interruption in patients enrolled in an open-label, multicenter, expanded-access study in myelofibrosis. Blood. 2014;124:5567.
41. J.Gotlib, V.Gupta, A.W.Roberts, et al. Update on the long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Blood. 2013;122:108.• Phase 1/2 study of momelotinib for treatment of myelofibrosis.
42. R.A.Abdelrahman, K.H.Begna, A.Al-Kali, et al. Momelotinib treatment-emergent neuropathy:prevalence, risk factors and outcome in 100 patients with myelofibrosis. Br J Haematol. 2015;169:77–80.
43. R.S.Komrokji, J.F.Seymour, A.W.Roberts, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 2015;125:2649–2655.
44. R.Mesa, E.Miklos, A.Szoke, et al. Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF). J Clin Oncol. 2015;33(suppl; abstr LBA7006).
45. CTI BioPharma Provides Update On Investigational Agent Pacritinb [Internet]. [cited 2016 Feb]. Available from:http://www.prnewswire.com/news-releases/cti-biopharma-provides-update-on-investigational-agent-pacritinib-300216412.html.•• Recent clinical hold put on pacritinib due to deaths in pacritinib-treated cohort.
46. A.Pardanani, C.Harrison, J.E.Cortes, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis:a randomized clinical trial. JAMA Oncol. 2015;1:643–651.
47. Q.Zhang, Y.Zhang, S.Diamond, et al. The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake:a putative mechanism for the onset of Wernicke’s encephalopathy. Drug Metab Dispos. 2014;42(10):1656–1662.
48. Summary of product characteristics of hydroxycarbamide by electronic medicines compendium [Internet]. [cited 2015 Nov]. Available from:https://www.medicines.org.uk/emc/medicine/18928.
49. E.Lofvenberg, A.Wahlin. Management of polcythaemia vera, essential thrombocythaemia, and myelofibrosis with hydroxyurea. Eur J Haematol. 1988;41:375–381.
50. A.Martínez-Trillos, A.Gaya, M.Maffioli, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis:results in 40 patients. Ann Hematol. 2010;89:1233–1237.
51. A.Tefferi, G.Barosi, R.A.Mesa, et al. International Working Group consensus criteria for treatment response in myelofibrosis with myeloid metaplasia:on behalf of the IWG for myelofibrosis research and treatment (IWG-MRT). Blood. 2006;108:1497–1503.
52. M.C.Petti, R.Latagliata, T.Spadea, et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;116:576–581.
53. J.J.Kiladjian, B.Cassinat, S.Chevret, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065–3072.
54. J.J.Kiladjian, C.Chomienne, P.Fenaux. Inerferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukaemia. 2008;22:1990–1998.
55. M.F.McMullin, D.Bareford, P.Campbell, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130:174–195.
56. C.N.Harrison, D.Bareford, N.Butt, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol. 2010;149:352–375.
57. A.Verma, D.K.Deb, A.Sassano, et al. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type 1 interferons and transforming growth factor-beta on normal haematopoiesis. J Biol Chem. 2002;277:7726–7735.
58. J.J.Kiladjian, R.A.Mesa, R.Hoffman. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011;117:4706–4715.
59. R.T.Silver, K.Vandris, J.J.Goldman. Recombinant interferon-alpha may retard progression of early primary myelofibrosis:a preliminary report. Blood. 2011;117:6669–6672.
60. J.C.Ianotto, F.Boyer-Perrard. Efficacy and safety of pegylated-interferon a-2a in myelofibrosis:a study by the FIM and GEM French cooperative groups. Br J Haematol. 2013;162:783–791.• Outcomes of interferon use in myelofibrosis.
61. E.Jonasch, F.Haluska. Interferon in oncological practice:review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6(1):34–55.
62. S.Mikkelsen, L.Kjaer, V.Skov, et al. Safety and efficacy of combination therapy of interferon-alpha2 + JAK1-2 inhibitor in the Philadelphia-negative chronic myeloproliferative neoplasms. Preliminary results from the Danish combi-trial – an open label, single arm, non-randomized multicenter phase II study [abstract]. Blood. 2015;126:824.
63. B.M.Kenton, F.Browne, R.J.D’Amato. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997;64:971–978.
64. R.A.Mesa, D.P.Steensma, A.Pardanani, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101:2534–2541.
65. P.Thapaliya, A.Tefferi, A.Pardanani, et al. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol. 2011;86:96–98.
66. A.Tefferi, J.Cortes, S.Verstovsek, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108:1158–1164.
67. R.Mesa, X.Yao, L.D.Cripe, et al. Lenalidomide and prednisolone for myelofibrosis:Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood. 2010;116:4436–4438.
68. A.Tefferi, S.Verstovsek, G.Barosi, et al. Pomalidomide is active in the treatment of anaemia associated with myelofibrosis. J Clin Oncol. 2009;27:4563–4569.
69. A.Tefferi, F.Passamonti, T.Barbui, et al. Phase 3 study of pomalidomide in myeloproliferative neoplasm (MPN)-associated myelofibrosis with RBC-transfusion-dependence [abstract]. Blood. 2013;122:394.
70. V.Levy, A.Bourgarit, A.Delmer, et al. Treatment of agnogenic myeloid metaplasia with danazol:a report of four cases. Am J Hematol. 1996;53:239–241.
71. F.Cervantes, A.Alvarez-Larran, A.Domingo, et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia:long-term results in 30 patients. Br J Haematol. 2005;129:771–775.
72. F.Cervantes, J.C.Hernandez-Boluda, A.Alvarez, et al. Danazol treatment of idiopathic myelofibrosis with severe anaemia. Haematologica. 2000;85:595–599.
73. S.N.Tsiara, A.Chaidos, L.K.Bourantas, et al. Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis. Acta Haematol. 2007;117:156–161.
74. F.Cervantes, A.Alvarez-Larrán, J.C.Hernández-Boluda, et al. Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol. 2006;134:184–186.
75. M.Breccia, M.Molica, G.Colafigli, et al. Improvement of bone marrow fibrosis with ruxolitinib:will this finding change our perception of the drug? Expert Rev Hematol. 2015;8(4):387–389.
76. E.Rumi, D.Pietra, C.Pascutto, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124:1062–1069.• Effect of key mutations on survival in myelofibrosis.
77. A.Pardanani, R.A.Abdelrahman, C.Finke, et al. Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. Leukemia. 2015;29:741–744.
78. K.P.Patel, K.J.Newberry, R.Luthra, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015;126:790–797.
79. The MPN Research Foundation has complied a list of trials; some of which are currently recruiting patients [Internet]. [cited 2016 Mar]. Available from:http://www.mpnresearchfoundation.org/Clinical-Trials.
80. P.Koppikar, N.Bhagwat, O.Kipivaara, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012;489:155–159.
81. N.Jaekel, G.Behre, A.Behning, et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant. 2014;49:179–184.•• Ruxolitinib use prior to allogeneic bone marrow transplantation.
82. M.Robin, S.Francois, A.Huynh, et al. Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis:a preliminary descriptive report of the JAK ALLO study, a phase II trial sponsored by Goelams-FIM in collaboration with the Sfgmtc. Blood. 2013;122:306.
83. R.Zeiser, A.Burchert, C.Lengerke, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation:a multicenter survey. Leukaemia. 2015;29:2062–2068.•• Ruxolitinib as a potential treatment for graft versus host disease.